Regulatoriskt pressmeddelande

Record quarter for Gubra, but revised outlook for the CRO business

Revenue and earnings for Gubra Group have been record-high in the second quarter of 2025 driven by the outlicensing deal with AbbVie in our Discovery & Partnerships business. While the CRO business also experienced revenue growth in the second quarter of 12% year-over-year, the full-year outlook for CRO revenue in 2025 has been revised to be slightly below CRO revenue level in 2024 (previous outlook 10-20% revenue growth). Outlook for EBIT-margin in the CRO business has been revised to around 20% (previously 25-31%).

Our CRO business has grown very significantly over the last two years where revenue has by far outpaced our mid-term annual growth guidance of 10%. In 2025, we have experienced a decline in revenue from the US driven by macroeconomic uncertainty encompassing a difficult funding environment for some of our customers. This has translated into longer decision timelines. The development in Europe is on the contrary sound. As a result of the slowdown we experience in the US, we have adjusted our full-year 2025 outlook for CRO revenue to be slightly below the CRO revenue level in 2024 (previous outlook 10-20% revenue growth). EBIT-margin outlook for full-year 2025 for the CRO business has been adjusted to be around 20% (previously 25-31%).

Outlook for 2025

Key ratio	New outlook for 2025	Previous outlook for 2025*
CRO Segment
Organic revenue growth	Revenue to be slightly below 2024	10-20% growth
EBIT-margin	Around 20%	25-31%
Discovery & Partnerships Segment
Total costs (adj. for special items)	DKK 230-250 million	DKK 230-250 million

* Previous outlook announced 9 May 2025

First half results 2025 will be published in Gubra’s half-year report 2025 on 21 August 2025.

About Gubra
Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 275 employees and in 2024 revenue of DKK 266 million. See www.gubra.dk for more information.